Alissa J. Cooper, MD, discusses insights from the TROPION-Lung01 trial that may help guide antibody-drug conjugate use in second-line NSCLC.
Alissa J. Cooper, MD
Advertisement
Articles by Alissa J. Cooper, MD
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
5